Signal Pharmaceuticals, Inc.

Ambit Biosciences Corporation

Ciba-geigy Corporation

Abbott Laboratories Corporation

Novartis Ag

Columbia University

Novartis Corporation

Nippon Kayaku Co., Ltd

Ambit Bioscience Corporation

Shripad S Bhagwat

Qi Chao

Yoshitaka Satoh

Kelly G Sprankle

Jeffrey A McKie

Guido Bold

Marc Lang

Alexander Fassler

Leah Marie Gayo-Fung

Martin W Rowbottom

Mark W Holladay

Eduardo Setti

Andiliy Gokching Lai

Brian T Campbell

Sunny Abraham

Bernd M Stein

Raffaella Faraoni

John J Sapienza

Hans-Georg Capraro

Adam Kois

Ronald J Albers

Chris Allen Buhr

Steven T Sakata

Kiran Sahasrabudhe

Veronique Plantevin

Rachel Ferri

Paul E Erdman

Kenneth D Rice

Satish Chandra Khanna

Anthony R Gangloff

Hitesh K Patel

Moorthy S S Palanki

Robert M Grotzfeld

Sak Khammungkhune

Mary Doubleday

Janis Karlis Lazdins

Marlon D Cowart

Stephan D Parent

Alan N Schwartz

Peter Schneider

W Clark Still

Philip R Hamann

Jason Parnes

Valeriya N Smolenskaya

Graziella I Shevlin

Brydon L Bennett

Brion William Murray

Johanne Renaud

Anthony M Manning

Alan J Main

Wei Lai

Martin Missbach

Herman Robert Rodriguez

David Wesley Anderson

Ravi Kumar Jalluri

Karen J MacFarlane

Eoin C O'Leary

Richard J Perner

Melanie Janelle Bevill

Moorthy S Palanki

Yu-Gui Gu

Peter Van Hoogevest

Hiroshi Sato

Melanie J Roe

May S Sutherland

Jason S Parnes

Karen J Macfarlane

Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

RAF kinase modulator compounds and methods of use thereof

Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.

Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Compositions of 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1, -trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O); Ris O or S. 

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

Imidazolothiazole compounds for the treatment of disease

Method of using imidazolothiazole compounds for the treatment of disease

Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure: wherein Rand Rare as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto

This invention generally relates to methods for treating or preventing a condition responsive to JNK inhibition, such as a metabolic condition, comprising administering to a patient in need thereof an effective amount of an Anilinopyrimidine Derivative having the following structure: or a pharmaceutically acceptable salt thereof, wherein Rthrough Rare as defined herein.

Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK

This invention generally relates to methods for treating or preventing an inflammatory disease or disorder comprising administering to a patient in need thereof an effective amount of a Pyrazoloanthrone Derivative having the following structure: or a pharmaceutically acceptable salt thereof, wherein Rand Rare as defined herein.

Methods for treating inflammatory conditions or inhibiting JNK

Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-&#x3b2; over ER-&#x3b1;. Methods are disclosed for modulating ER-&#x3b2; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-&#x3b2;. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

Compounds and methods for modulation of estrogen receptors

Benzopyranone Compounds having the following structure: 

Benzopyranone compounds, compositions thereof, and methods of treatment therewith

Growing community of inventors

San Diego, CA, United States of America

Shripad S Bhagwat